Arzneimittel mit dem Wirkstoff Entecavir (ATC: J05AF10 - in der Darreichungsform Filmtabletten)

TENDER DESCRIPTION

Conclusion of non-exclusive rebate agreements pursuant to § 130a para. 8 SGB V for finished medicinal products containing the active substance Entecavir (ATC: J05AF10 - in the dosage form of film-coated tablets) with the possibility to conclude contracts at any time within the framework of a so-called "open-house model." A contract is concluded with every pharmaceutical company that meets the participation requirements. Exclusivity is not granted. Accession or contract conclusion can take place at any time and under the same conditions. Individual contract negotiations are not conducted. The earliest contract start date is 01.10.2026. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.09.2028 regardless of the contract start date. Should AOK Saxony-Anhalt publish exclusive contracts for the active substances during the contract period in accordance with the applicable public procurement provisions, the contracts concluded within the scope of this publication will be terminated in accordance with the contractual provisions. This publication does not constitute the award of a public contract within the meaning of § 103 GWB or public procurement…

TENDER BRIEF

TENDER DOCUMENTS